US patent reforms could re-establish gene patent eligibility, industry experts warn
06-06-2019
Gilead claims US government PrEP patents are invalid
20-05-2019
Generic of Gilead’s HIV pre-exposure drug coming to market in 2020
09-05-2019
roschetzky / iStockphoto
The Information Technology and Innovation Foundation (ITIF) think tank has called on the US National Institutions of Health (NIH) to maintain IP protection amid calls to “break” patents in order to lower drug prices.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Information Technology and Innovation Foundation, report, PrEP, National Institutes of Health, patent breaking, innovation, prices, Truvada, Bayh-Dole Act
